RFS according to FLT3-ITD MRD detected before or after HCT. (A) RFS by randomization arm for all participants with FLT3-ITD MRD detected immediately before beginning pre-HCT conditioning. (B) RFS by randomization arm for all participants with FLT3-ITD MRD detected after engraftment was confirmed and before randomization to either gilteritinib or placebo. 95% CI, 95% confidence interval; HR, hazard ratio.